Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium

Gerald L. Murray, Catriona S. Bradshaw, Melanie Bissessor, Jennifer A Danielewski, Suzanne M. Garland, Jørgen S. Jensen, Christopher K. Fairley, Sepehr N. Tabrizi

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.

Original languageEnglish
Pages (from-to)809-812
Number of pages4
JournalEmerging infectious diseases
Volume23
Issue number5
DOIs
Publication statusPublished - 1 May 2017

Cite this

Murray, G. L., Bradshaw, C. S., Bissessor, M., Danielewski, J. A., Garland, S. M., Jensen, J. S., ... Tabrizi, S. N. (2017). Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerging infectious diseases, 23(5), 809-812. https://doi.org/10.3201/eid2305.161745
Murray, Gerald L. ; Bradshaw, Catriona S. ; Bissessor, Melanie ; Danielewski, Jennifer A ; Garland, Suzanne M. ; Jensen, Jørgen S. ; Fairley, Christopher K. ; Tabrizi, Sepehr N. / Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. In: Emerging infectious diseases. 2017 ; Vol. 23, No. 5. pp. 809-812.
@article{283e57cbffff4a95b8ed4d20a8b952a0,
title = "Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium",
abstract = "Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6{\%}) and gyrA (5{\%}). ParC S83 changes were associated with moxifloxacin failure. Macrolide/fluoroquinolone-resistance mutations were in 8.6{\%} of specimens, for which recommended therapies would be ineffective.",
author = "Murray, {Gerald L.} and Bradshaw, {Catriona S.} and Melanie Bissessor and Danielewski, {Jennifer A} and Garland, {Suzanne M.} and Jensen, {J{\o}rgen S.} and Fairley, {Christopher K.} and Tabrizi, {Sepehr N.}",
year = "2017",
month = "5",
day = "1",
doi = "10.3201/eid2305.161745",
language = "English",
volume = "23",
pages = "809--812",
journal = "Emerging infectious diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention",
number = "5",

}

Murray, GL, Bradshaw, CS, Bissessor, M, Danielewski, JA, Garland, SM, Jensen, JS, Fairley, CK & Tabrizi, SN 2017, 'Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium' Emerging infectious diseases, vol. 23, no. 5, pp. 809-812. https://doi.org/10.3201/eid2305.161745

Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. / Murray, Gerald L.; Bradshaw, Catriona S.; Bissessor, Melanie; Danielewski, Jennifer A; Garland, Suzanne M.; Jensen, Jørgen S.; Fairley, Christopher K.; Tabrizi, Sepehr N.

In: Emerging infectious diseases, Vol. 23, No. 5, 01.05.2017, p. 809-812.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium

AU - Murray, Gerald L.

AU - Bradshaw, Catriona S.

AU - Bissessor, Melanie

AU - Danielewski, Jennifer A

AU - Garland, Suzanne M.

AU - Jensen, Jørgen S.

AU - Fairley, Christopher K.

AU - Tabrizi, Sepehr N.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.

AB - Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.

UR - http://www.scopus.com/inward/record.url?scp=85017771129&partnerID=8YFLogxK

U2 - 10.3201/eid2305.161745

DO - 10.3201/eid2305.161745

M3 - Article

VL - 23

SP - 809

EP - 812

JO - Emerging infectious diseases

JF - Emerging infectious diseases

SN - 1080-6040

IS - 5

ER -